VIRTUOSO THERAPEUTICS
Virtuoso Therapeutics, Inc. is focused on bi-specific antibody drug discovery and development for oncology indication.
VIRTUOSO THERAPEUTICS
Industry:
Biotechnology Health Care Oncology
Founded:
2019-01-01
Address:
San Mateo, California, United States
Country:
United States
Website Url:
http://www.virtuosotherapeutics.com
Status:
Active
Technology used in webpage:
Cloudflare Hosting Gravity Forms
Similar Organizations
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Coriell Life Sciences
Coriell Life Sciences delivers the power of precision medicine using pharmacogenomics and clinical decision support software.
Group K Diagnostics
We put patient health 1st by revolutionizing rapid blood testing with a hand-held chemistry and ID analyzer for everyone, all in one.
Immunitas Therapeutics
Immunitas Therapeutics is a single cell genomics-based drug discovery company that modulates oncology targets.
Longevity Biotech
Longevity Biotech develops a new class of therapeutics via artificial protein technology that focuses on pharmaceutical preparation.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Raze Therapeutics
Raze Therapeutics, Inc., a biotechnology company, engages in the discovery and development of oncology therapeutics.
ENU Nutrition
ENU Nutrition develops and commercializes nutritional products.
Current Employees Featured
Founder
Official Site Inspections
http://www.virtuosotherapeutics.com
Unable to get host informations!!!
More informations about "Virtuoso Therapeutics"
Virtuoso Therapeutics
Advancing novel bispecific antibodies to treat cancer. Leveraging our technology, unique insights and capabilities to develop bispecifics with superior profiles. Advancing programs to improve โฆSee details»
Company | Virtuoso Therapeutics
Virtuoso Therapeutics is an oncology-focused company developing novel bispecific antibody therapies. Our teamโs expertise and insights could address some of the fundamental challenges of these modalities, such as efficacy and โฆSee details»
Our Approach | Virtuoso Therapeutics
We utilize a number of design principles to develop our bispecific antibodies, with the main objective of enhancing potency and selectivity. One approach we use is the โGuide x Effectorโ โฆSee details»
Virtuoso Therapeutics - Crunchbase Company Profile
Virtuoso Therapeutics, Inc. is focused on bi-specific antibody drug discovery and development for oncology indication. There is no recent news or activity for this profile. Where is Virtuoso Therapeutics's headquarters? Virtuoso Therapeutics โฆSee details»
Virtuoso Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Nov 1, 2024ย ยท Virtuoso Therapeutics is a company with a primary focus on oncology, specializing in the development of innovative bispecific antibody therapies. The leadership team at โฆSee details»
Virtuoso Therapeutics to Present Preclinical Findings on Two Best โฆ
Mar 23, 2022ย ยท Virtuoso bispecific antibodies confer greater tumor selectivity than monoclonal antibodies. This greater selectivity allows enhanced efficacy with strong effector functions, and โฆSee details»
Virtuoso Therapeutics - VentureRadar
Website: http://www.virtuosotherapeutics.com/ Virtuoso Therapeutics, Inc. is focused on bi-specific antibody drug discovery and development for oncology indication. The company was โฆSee details»
Virtuoso Therapeutics Company Profile | Management and
Virtuoso Therapeutics is an oncology-focused company developing novel bispecific antibody and ADC therapies. The team's expertise and insights could address some of the fundamental โฆSee details»
Virtuoso Therapeutics to Present Preclinical Findings on
SAN MATEO, Calif., April 11, 2023 /PRNewswire/ -- Virtuoso Therapeutics, Inc., a private oncology-focused company developing novel bispecific antibodies today announced that it will โฆSee details»
Virtuoso Therapeutics to Present Preclinical Findings on ... - BioSpace
Apr 11, 2023ย ยท Virtuoso Therapeutics is an oncology-focused company developing novel bispecific antibodies. The teamโs expertise and insights could address some of the fundamental โฆSee details»
Virtuoso Therapeutics - Overview, News & Similar companies
View Virtuoso Therapeutics (www.virtuosotherapeutics.com) location in California, United States , revenue, industry and description. Find related and similar companies as well as employees โฆSee details»
Virtuoso Therapeutics - PitchBook
Information on valuation, funding, cap tables, investors, and executives for Virtuoso Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Pipeline - Virtuoso Therapeutics
We are rapidly advancing our pipeline of novel bi-specific antibodies for the treatment of cancer. For more information on how we select, design and advance our programs, please visit Our โฆSee details»
Sofie Qiao - President and Chief Executive Officer - Crunchbase
Dr. Qiao is the founding president and CEO of Vivace Therapeutics & Virtuoso Therapeutics. Sofie Qiao previously worked at WuXi AppTec as Managing Director, Wuxi Venture Fund. She โฆSee details»
Virtuoso Therapeutics to Present Preclinical Findings on Two
Mar 23, 2022ย ยท Virtuoso Therapeutics, Inc. today announced that it will present two posters highlighting the preclinical data from leading bispecific antibody programs at the American โฆSee details»
Sofie Qiao, Ph.D. | Virtuoso Therapeutics
Sofie Qiao, Ph.D., founded Virtuoso and has served as its President and Chief Executive Officer since its inception. Dr. Qiao was also the founding President and CEO of Vivace Therapeutics. โฆSee details»
Virtuoso Therapeutics | Insights
Oct 6, 2023ย ยท Designed to bring ease and precision to complex procedures, surgical robots are slowly but surely becoming the preferred tool for surgeons worldwide. In soft tissue, the โฆSee details»
Virtuoso Therapeutics, Inc. (Virtuoso Therapeutics, Inc.) - ่ฏ็ฉ็ฎก โฆ
To effectively target CD38 on tumor cells, we generated an antibody-dependent cellular cytotoxicity (ADCC) enhanced bispecific CD38 x intercellular cell adhesion molecule 1 (ICAM โฆSee details»
AACR 2023 - Virtuoso Therapeutics
To improve the effectiveness of targeting ICAM-1, we developed a novel ICAM-1 antibody drug conjugate (ADC) consisting of a humanized anti-ICAM-1 IgG1 antibody conjugated with a โฆSee details»
Multiple Modes of Action of the CD38 x ICAM-1 Bispecific Antibody
VP301 showed potent in vitro ADCC activities on ICAM-1+ tumor cells with medium to low CD38 levels, where the benchmark dara has low or minimal effect. ADCC was tested on Raji โฆSee details»